- BioVector NTCC典型培养物保藏中心
- 联系人:Dr.Xu, Biovector NTCC Inc.
电话:400-800-2947 工作微信:1843439339 (QQ同号)
邮件:Biovector@163.com
手机:18901268599
地址:北京
- 已注册
HCC1569 cells细胞株 BioVector NTCC质粒载体菌种细胞基因保藏中心 Designations: HCC1569
Depositors: AF Gazdar, AK Virmani
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: mixed adherent-suspension
Organism: Homo sapiens
Morphology: epithelial
Source: Organ: mammary gland; breast
Tumor Stage: TNM stage IV, grade 3
Disease: primary metaplastic carcinoma
Cellular Products: Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Applications: The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR) by immunohistochemistry, but PR expression was detectable at a low level by cytosolic protein assay.
The cells are poorly differentiated.
The cells are positive for expression of Her2-neu and negative for expression of p53.
HCC1569 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cell line is derived from an older patient with a germline mutation in the FHIT gene.
Receptors: estrogen receptor, negative
progesterone receptor, negative
Oncogene: her2/neu +, p53 -
Cytogenetic Analysis: polyploid
Age: 70
Gender: female
Ethnicity: Black
Comments: This cell line was initiated on 3/8/95 and took 19 months to establish.
The patient received prior chemotherapy and had no family history of breast cancer. The tumor was classified as TNM stage IV, grade 3, metaplastic carcinoma with 4 out of 18 lymph node metastasis.
The cells are poorly differentiated.
The cells are positive for expression of Her2-neu and negative for expression of p53.
HCC1569 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR) by immunohistochemistry, but PR expression was detectable at a low level by cytosolic protein assay.
The cell line is derived from an older patient with a germline mutation in the FHIT gene. The FHIT gene is located at 3p14.2 and the mutation is a transversion at nucleotide 651 (G to T).The patient's daughter carries the same gene mutation.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Protocol:
1. Remove culture medium to a centrifuge tube.
2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually with 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37�C to facilitate dispersal.
4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5. To remove trypsin-EDTA solution, transfer cell suspension to the centrifuge tube with the medium and cells from step #1 and spin at approximately 125 xg for 5 to 10 minutes.
6. Discard supernatant and resuspend cells in fresh growth medium. Add appropriate aliquots of cell suspension to new culture vessels.
7. Place culture vessels in incubators at 37�C.
Preservation: culture medium 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 32258: Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768
38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心
电话:+86-010-53513060
网址:www.biovector.net [Supplier来源] http://www.biovector.net
Depositors: AF Gazdar, AK Virmani
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: mixed adherent-suspension
Organism: Homo sapiens
Morphology: epithelial
Source: Organ: mammary gland; breast
Tumor Stage: TNM stage IV, grade 3
Disease: primary metaplastic carcinoma
Cellular Products: Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Applications: The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR) by immunohistochemistry, but PR expression was detectable at a low level by cytosolic protein assay.
The cells are poorly differentiated.
The cells are positive for expression of Her2-neu and negative for expression of p53.
HCC1569 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cell line is derived from an older patient with a germline mutation in the FHIT gene.
Receptors: estrogen receptor, negative
progesterone receptor, negative
Oncogene: her2/neu +, p53 -
Cytogenetic Analysis: polyploid
Age: 70
Gender: female
Ethnicity: Black
Comments: This cell line was initiated on 3/8/95 and took 19 months to establish.
The patient received prior chemotherapy and had no family history of breast cancer. The tumor was classified as TNM stage IV, grade 3, metaplastic carcinoma with 4 out of 18 lymph node metastasis.
The cells are poorly differentiated.
The cells are positive for expression of Her2-neu and negative for expression of p53.
HCC1569 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR) by immunohistochemistry, but PR expression was detectable at a low level by cytosolic protein assay.
The cell line is derived from an older patient with a germline mutation in the FHIT gene. The FHIT gene is located at 3p14.2 and the mutation is a transversion at nucleotide 651 (G to T).The patient's daughter carries the same gene mutation.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Protocol:
1. Remove culture medium to a centrifuge tube.
2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually with 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37�C to facilitate dispersal.
4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5. To remove trypsin-EDTA solution, transfer cell suspension to the centrifuge tube with the medium and cells from step #1 and spin at approximately 125 xg for 5 to 10 minutes.
6. Discard supernatant and resuspend cells in fresh growth medium. Add appropriate aliquots of cell suspension to new culture vessels.
7. Place culture vessels in incubators at 37�C.
Preservation: culture medium 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 32258: Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768
38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心
电话:+86-010-53513060
网址:www.biovector.net [Supplier来源] http://www.biovector.net
您正在向 biovector.net 发送关于产品 HCC1569 cells细胞株 BioVector NTCC质粒载体菌种细胞基因保藏中心 的询问
- 公告/新闻




